abstract |
Compounds of formula I are described that are useful for the treatment of cancer, autoimmune diseases and metabolic bone disorders through the inhibition of c-FMS (CSF-1R), c-KIT, and / or PDGFR kinases. These compounds are also useful for the treatment of other diseases of mammals mediated by c-FMS, c-KIT or PDGFR kinases. |